Actively Recruiting
Screening for Type 2 Diabetes by Oral Glucose Tolerance Test in the Population Groups Not Diagnosed by Fasting Blood Glucose in Guadeloupe
Led by Centre Hospitalier Universitaire de la Guadeloupe · Updated on 2025-11-18
120
Participants Needed
1
Research Sites
391 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In France, only the fasting blood glucose (FBG) measurement is recommended for diabetes screening. Ethnic heterogeneity and genetic polymorphisms specific to the Afro-Caribbean and Indo-Caribbean population in Guadeloupe justify the interest to early screen type 2 diabetes mellitus (T2DM). Our main objective is to estimate the prevalence of T2DM defined by oral glucose tolerance (OGTT) in subjects with risk factors for T2DM and not diagnosed with the FBG.
CONDITIONS
Official Title
Screening for Type 2 Diabetes by Oral Glucose Tolerance Test in the Population Groups Not Diagnosed by Fasting Blood Glucose in Guadeloupe
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged over 18 and under 65 years
- Subjects of African or Indian origin who self-identify as such
- Normal fasting blood glucose levels below 110 mg/dL
- HbA1c levels between 5.7% and 6.4%
- Presence of one or more risk factors: BMI over 25 kg/m2, family history of type 2 diabetes in 1st or 2nd degree relatives, hypertension, or dyslipidemia
- Affiliation to the national social health system or equivalent
- Signed informed consent by the participant and investigator before any study exams
You will not qualify if you...
- Pregnant or breastfeeding women
- Women with a history of gestational diabetes
- Diagnosis of polycystic ovary syndrome
- Endocrine, liver, or kidney diseases affecting blood sugar control
- Current treatment affecting glucose or insulin metabolism
- Refusal to participate in the study
- Inability to give informed consent due to impaired decision-making or legal guardianship
- Participation in another ongoing research study with an exclusion period
- Severe physical or psychological health issues that may affect study compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Universitaire de la Guadeloupe
Pointe-à-Pitre, Guadeloupe, Guadeloupe, 97159
Actively Recruiting
Research Team
V
Valérie HAMONY-SOTER
CONTACT
E
Eunice NUBRET
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here